Loading…
← CockpitCompetitor Analysis › JANX Janux Therapeutics, Inc.Open in the cockpit ↗

Janux Therapeutics, Inc.JANXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 10
Mkt cap
$631M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.9%
Hurdle
n/a
no reverse DCF
Next earnings
107 days
5 Mar 2027
Close · USD$10.31
1D-3.7%
1W-16.8%
1M-40.1%
3M-40.3%
6M-28.4%
YTD-25.3%
1Y-64.1%
ATR %10.3%
Beta0.95
52w lowhigh70.8% off high

What Janux Therapeutics does

Employees: 109

Janux Therapeutics at a glance

Size Janux Therapeutics (JANX) is a United States Health Care company (Biotechnology) with a market value of $631M, the 2523rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.31 on 18 Nov 2026.

Performance Over six months the shares fell 28.4%, against -12.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 132.9% over the last twelve months (peer median +18.4%); the operating margin is -599.3% (peer median -92.0%).

Short interest Short interest is 8.7% of the free float (30 Oct 2026).

Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 87JANX 72
Six months, rebased to 100: Janux Therapeutics against the median of its 20 peers (local-currency closes).

Janux Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$23.3M$10.0M$10.6M$8.08M$8.61M
Revenue growth—-6%+31%-6%—
Gross profit$21.4M$7.97M$8.53M$6.13M$7.77M
EBITDA-$138M-$156M-$96.8M-$71.0M-$66.2M
Net income-$99.8M-$114M-$69.0M-$58.3M-$63.1M
Free cash flow-$54.2M-$83.3M-$44.2M-$52.4M-$49.4M
Capital expenditure$583,000$1.04M$359,000$1.85M$6.45M
Total debt$20.4M$22.1M$23.0M$24.5M$25.3M

Quarterly statements and history in the cockpit →

Janux Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%002880603387GERN688197DSGNSRZN99667729PRMEGNFTATTOJANX6-month return →1-month return →
Up and to the right = strong over both horizons. Janux Therapeutics is the large dot.

Janux Therapeutics competitors and peer comparison

How Janux Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Janux Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureJANXPeer medianRank in peer set
1-month return-40.1%-10.6%lowest of 21
6-month return-28.4%-12.9%6th lowest of 20
Distance from 52-week high-70.8%-44.5%2nd lowest of 21
Revenue growth (TTM)+132.9%+18.4%6th highest of 17
Operating margin-599.3%-92.0%4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a

Questions

Which companies are Janux Therapeutics's closest peers?
The cockpit's peer set: Shenzhen Weiguang Biological Products (002880.SZ), Getein Biotech (603387.SS), Geron (GERN), Shouyao Holdings Beijing (688197.SS), Design Therapeutics (DSGN), Surrozen (SRZN), Anhui Huaheng Biotechnology (688639.SS), Frontier Biotechnologies (688221.SS).
How has Janux Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -28.4% against -12.9% for the median peer; over one year -64.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.